


Please add the following new claims:

--73. A method of treating a neurological disorder in an animal, comprising:


administering to the animal an effective amount of a compound to stimulate growth of damaged peripheral nerves or to promote neuronal regeneration, wherein the compound has the formula (I):



where

X, Y, and Z are independently selected from the group consisting of C, O, S, or N, provided that X, Y, and Z are not all C;


n is 1;



R<sub>1</sub> is selected from the group consisting of hydrogen, C<sub>1</sub>-C<sub>9</sub> straight or branched chain alkyl, C<sub>2</sub>-C<sub>9</sub> straight or branched chain alkenyl, aryl, heteroaryl, carbocycle, and heterocycle;

D is selected from the group consisting of a bond, C<sub>1</sub>-C<sub>10</sub> straight or branched chain alkylene, ethylene (-CH=CH-), and butylene;

R<sub>2</sub> is a carboxylic acid or a carboxylic acid isostere selected from the group consisting of:



wherein said alkyl, alkenyl, alkylene, ethylene, butylene, aryl, heteroaryl, carbocycle, heterocycle, or carboxylic acid isostere is optionally substituted with one or more substituents selected from  $R_3$ , where

$R_3$  is selected from the group consisting of hydrogen, hydroxy,

halo, haloalkyl, thiocarbonyl, alkoxy, alkenoxy, alkylaryloxy, aryloxy, arylalkyloxy, cyano, nitro, imino, alkylamino, aminoalkyl, sulfhydryl, thioalkyl, alkylthio, sulfonyl, C<sub>1</sub>-C<sub>6</sub> straight or branched chain alkyl, C<sub>2</sub>-C<sub>6</sub> straight or branched chain alkenyl or alkynyl, aryl, heteroaryl, carbocycle, heterocycle, and CO<sub>2</sub>R<sub>4</sub> where R<sub>4</sub> is selected from the group consisting of hydrogen, C<sub>1</sub>-C<sub>9</sub> straight or branched chain alkyl, and C<sub>2</sub>-C<sub>9</sub> straight or branched chain alkenyl;

or a pharmaceutically acceptable salt, or solvate thereof.

B<sub>1</sub> 74. The method of claim 73, wherein the neurological disorder is selected from the group consisting of peripheral neuropathies caused by physical injury or disease state, physical damage to the brain, physical damage to the spinal cord, stroke associated with brain damage, and neurological disorders relating to neurodegeneration.

75. The method of claim 73, wherein the neurological disorder is selected from the group consisting of Alzheimer's Disease, Parkinson's Disease, and amyotrophic lateral sclerosis.


76. The method of claim 73, wherein the neurological disorder is Alzheimer's Disease.

77. The method of claim 73, wherein the neurological disorder is amyotrophic lateral sclerosis.

78. The method of claim 73, wherein said compound is non-


immunosuppressive.

79. The method of claim 73, wherein the compound is selected from the group consisting of:



80. A method of treating a neurological disorder in an animal, comprising:

administering to the animal an effective amount of a compound to stimulate growth of damaged peripheral nerves or to promote neuronal regeneration, wherein the compound has the formula (I):




where

X, Y, and Z are independently selected from the group consisting of

C, O, S, or N, provided that X, Y, and Z are not all C;

n is 1;

A is



R<sub>1</sub> is selected from the group consisting of hydrogen, C<sub>1</sub>-C<sub>9</sub> straight or branched chain alkyl, C<sub>2</sub>-C<sub>9</sub> straight or branched chain alkenyl, aryl, heteroaryl, carbocycle, and heterocycle;

D is selected from the group consisting of a bond, C<sub>1</sub>-C<sub>10</sub> straight or branched chain alkylene, ethylene (-CH=CH-), and butylene;

R<sub>2</sub> is a carboxylic acid or carboxylic acid isostere selected from the group consisting of:

-COOH, -SO<sub>3</sub>H, -SO<sub>2</sub>HNR<sub>3</sub>, -PO<sub>2</sub>(R<sub>3</sub>)<sub>2</sub>, -CN, -PO<sub>3</sub>(R<sub>3</sub>)<sub>2</sub>, -OR<sub>3</sub>, -SR<sub>3</sub>,  
-NHCOR<sub>3</sub>, -N(R<sub>3</sub>)<sub>2</sub>, -CON(R<sub>3</sub>)<sub>2</sub>, -CONH(O)R<sub>3</sub>, -CONHNHSO<sub>2</sub>R<sub>3</sub>,  
-COHNSO<sub>2</sub>R<sub>3</sub>, and -CONR<sub>3</sub>CN;

wherein said alkyl, alkenyl, alkylene, ethylene, butylene, aryl, heteroaryl, carbocycle, heterocycle, or carboxylic acid isostere is optionally substituted with one or more substituents selected from R<sub>3</sub>, where

R<sub>3</sub> is selected from the group consisting of hydrogen, hydroxy, halo, haloalkyl, thiocarbonyl, alkoxy, alkenoxy, alkylaryloxy, aryloxy, arylalkyloxy, cyano, nitro, imino, alkylamino, aminoalkyl, sulfhydryl, thioalkyl, alkylthio, sulfonyl, C<sub>1</sub>-C<sub>6</sub> straight or branched chain alkyl, C<sub>2</sub>-C<sub>6</sub> straight or branched chain alkenyl or alkynyl, aryl, heteroaryl, carbocycle, heterocycle, and CO<sub>2</sub>R<sub>4</sub> where R<sub>4</sub> is selected from the group consisting of hydrogen, C<sub>1</sub>-C<sub>9</sub> straight or branched chain alkyl, and C<sub>2</sub>-C<sub>9</sub> straight or branched chain alkenyl;

or a pharmaceutically acceptable salt, or solvate thereof.

81. The method of claim 80, wherein the neurological disorder is selected from the group consisting of peripheral neuropathies caused by physical injury or disease state, physical damage to the brain, physical damage to the spinal cord, stroke associated with brain damage, and neurological disorders relating to neurodegeneration.

82. The method of claim 80, wherein the neurological disorder is selected from the group consisting of Alzheimer's Disease, Parkinson's Disease, and amyotrophic lateral sclerosis.

83. The method of claim 80, wherein the neurological disorder is Alzheimer's Disease.

84. The method of claim 80, wherein the neurological disorder is amyotrophic lateral sclerosis.

85. The method of claim 80, wherein said compound is non-immunosuppressive.

86. The method of claim 80, wherein the compound is selected from the group consisting of:

